Albany, NY -- (SBWIRE) -- 03/09/2017 -- Global Alpha Mannosidosis Market: Regional Outlook
Geographically, the market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific is expected to dominate the market in 2017 with a considerable market share. North America and Europe also account for substantial portion of the market. The report identifies and explains key market drivers, restraints and opportunities. The report also provides Porter's five forces analysis for comprehensive market understanding. Furthermore, market attractiveness analysis provides insights to most attractive regional markets to invest in the future.
Global Alpha Mannosidosis Market: Overview
With increase in the incidence of alpha mannosidosis worldwide the market for treatment is expected to grow in coming years. Alpha Mannosidosis is a rare inherited condition that leads to problems in organs and tissues of the body. The disease is of three types such as Type I, Type II and Type III. Type I is a mild form, type II is moderate form of disease and most commonly observed, whereas, type III is the severe form of disease. Alpha Mannosidosis affects 1 in every 10, 00,000 people worldwide. Alpha-mannosidosis affects men and women equally across the globe. Bone marrow transplant (BMT) and Enzyme replacement therapy (ERT) are the two treatment options for alpha mannosidosis. Bone marrow transplant (BMT) has been conventionally used universally to treat patients suffering from alpha mannosidosis.
Some of the factors driving this market include market exclusivity of orphan drugs, fee reductions and tax credits, increasing investment in the rare disease treatment etc. However, the factors such as high cost of orphan drugs and lack of awareness are expected to hamper the market demand.
Browse full report on Alpha Mannosidosis Market -
Global Alpha Mannosidosis Market: Segmentation
The alpha mannosidosis market has been segmented based on treatment, indication, end-user and geography. Based on treatment, the market has been segmented into bone marrow transplant (BMT) and enzyme replacement therapy (ERT). Enzyme replacement therapy (ERT) is expected to dominate the market with a considerable share in 2017. With the expected increase in the incidence of alpha mannosidosis the market is expected to grow at a high rate in the next few years. BMT is expected to grow steadily due to the morbidity issues connected with the treatment. In terms of indication, the market has been categorized into type I, type II and type III. The market for type III segment is projected to expand at the maximum rate during the forecast period. Type II accounts for a considerable market share at present. Based on end-user, the market has been segmented into hospitals and specialty clinics. The hospitals segment dominated the market and the trend is likely to continue driven by increasing patient burden due to rise in patient burden.
Key Players Mentioned in this Research Report are:
Zymenex, a company focused on R&D on biologics designed to fight rare and life-threatening genetic diseases has developed recombinant enzyme indicated for patients with alpha-Mannosidosis known as Lamazym (velmanase alfa). Zymenex has been acquired by Chiesi Farmaceutici S.p.A. Lamazym has received orphan drug designation is Europe and the U.S.
Request for Sample of this report -